We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Achillion Pharmaceuticals, Inc. (“Achillion” or the “Company”) (NASDAQ: ACHN) to Alexion Pharmaceuticals, Inc. (“Alexion”) (NASDAQ: ALXN). Under the terms of the deal, shareholders of Achillion will receive $6.50 in cash, plus potential additional contingent considerations for each share of Achillion they own.
The Achillion merger investigation concerns whether the Board of Achillion breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Alexion is underpaying for Achillion, thus unlawfully harming Achillion shareholders.
To receive more information, please fill out the form.